OPKO HEALTH, INC.

OPKO Health operates across diagnostics and pharmaceuticals, with its diagnostics business centered on BioReference Laboratories, which provides laboratory testing services including esoteric testing, molecular diagnostics, anatomical pathology, genetics, and women's health screening to physician offices, hospitals, employers, and government entities. The company also offers the 4Kscore prostate cancer test. In pharmaceuticals, OPKO commercializes Rayaldee for secondary hyperparathyroidism in chronic kidney disease patients and maintains a pipeline of therapies in development, including selective androgen receptor modulators, peptides for type 2 diabetes and obesity, and longer-acting versions of approved therapeutic proteins. The company also manufactures and distributes generic pharmaceuticals, nutraceutical products, and over-the-counter medications across various therapeutic categories.

The company operates through established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, alongside its primary U.S. diagnostics operations. OPKO's business spans laboratory services revenue from BioReference, pharmaceutical product sales from its commercial portfolio and manufacturing operations, and potential future revenues from pipeline candidates. The company employs approximately 2,997 full-time employees and maintains headquarters in Miami, Florida, with international operations supporting its diversified product offerings across multiple geographies.